PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.61
0.13 (5.24%)
▲
5d:
+9.66%
30d:
+14.98%
90d:
+24.29%
WAIT
LOW Confidence
Analysis Updated: Aug 27, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PLX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PLX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.61, which is considered extended relative to its 30-day fair value range of $2.30 to $2.48. From a valuation perspective, the stock is trading at a premium (Forward PE: 47.5) compared to its historical average (31.7). At these levels, the market is pricing in 14.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PLX is in a uptrend. The price is approaching resistance at $2.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: PLX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+321.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLX is in a uptrend. The price is approaching resistance at $2.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: PLX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+321.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.30 -
$2.48
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range (+5.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.2%)
- BULLISH: Trading 321.5% below Wall St target ($11.00)
- NEUTRAL: PE elevated vs history but 14.3% growth expectation is conservative given 2241% recent growth
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.30 -
$2.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.17
Resistance Level
$2.65
Current Trend
Uptrend
Technical data as of
Aug 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
47.45
Wall Street Target
$11.00
(+321.5%)
Revenue Growth (YoY)
27.1%
Earnings Growth (YoY)
2241.1%
Profit Margin
23.5%
Valuation Premium vs History
+14.3% premium
PE vs Historical
47.5 vs 31.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+14.3%
(market-implied from PE analysis)
1-Year Target
$2.98
(+14%)
2-Year Target
$3.41
(+31%)
3-Year Target
$3.90
(+49%)
3-Yr Target (if PE normalizes)
(PE: 47→32)
PE COMPRESSION
$2.60
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 47.5, Growth: -71.1%)
$1.90
(+-27%)
Base:
(SPY PE: 20.1, Growth: -71.1%)
$0.80
(-69%)
Bear:
(PE: 17.1, Growth: -71.1%)
$0.68
(-74%)
📈
Valuation based on Current Earnings
Trailing PE: 10.78 | Current EPS (TTM): $0.23
Bull Case
$1.36
(-48%)
Analyst growth -50.0%, PE expands to 11.9
Base Case
$1.24
(-53%)
Market implied -50.0%, PE stable at 10.8
Bear Case
$1.69
(-35%)
Severe decline -20.0%, PE contracts to 9.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 27, 2026 9:17 PM ET
Data refreshes hourly during market hours. Next update: 10:17 PM
Data refreshes hourly during market hours. Next update: 10:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 39 SELL |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 29 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 43 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 56 HOLD |
